Bioventus develops and markets orthobiologic and restorative therapies for bone healing, joint pain, and soft-tissue conditions. Flagship offerings include the EXOGEN ultrasound bone-healing system and hyaluronic-acid and other injectables used in osteoarthritis and related musculoskeletal care. Products serve orthopedic surgeons, sports-medicine clinicians, and pain specialists treating patients outside major reconstructive surgery. The company sits at the intersection of devices and biologics within the musculoskeletal treatment pathway.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 123.9 | — | -2.6 | — |
| Q2 2025 | 147.7 | — | 7.5 | — |
| Q3 2025 | 138.7 | — | 3.1 | — |
| Q4 2025 | 157.9 | — | 14.8 | — |
| Q1 2026 | 132.1 | 6.6% | 3.1 | — |
| Q2 2026 | 153.2 | 3.8% | 33.4 | 348.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Farmers National Banc Corp. (FMNB), Sinclair, Inc. (SBGI), American Public Education, Inc. (APEI), Willis Lease Finance Corporation (WLFC), Braiin Limited (BRAI), MeiraGTx Holdings plc (MGTX)